SYNERGY: Tofisopam has obtained the drug registration certificate in South Korea
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, SYNERGY announced that the company recently received the drug registration certificate for tolvaptan from the Ministry of Food and Drug Safety (MFDS) of South Korea. Tolvaptan is an oral anticoagulant primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments